1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

ENZ, MOS, RBN, FTI - Stock Watch From DrStockPick.com!

Enzo Biochem, Inc. (NYSE:ENZ) is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and provides reference laboratory services to the medical community.

 
PRLog - Jan. 3, 2011 - Enzo Biochem, Inc. (NYSE:ENZ) is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and provides reference laboratory services to the medical community.

Enzo technologies and products are recognized as the key tools in non-radioactive gene labeling used by researchers worldwide. Additionally, Enzo's work in gene analysis has led to development of a number of significant therapeutic candidates for the treatment of viral and immunological based disorders, several of which are in various phases of human clinical trials. In the course of our extensive research and development activities, we have built a significant patent position consisting of numerous pioneer patents and applications that encompass our core technologies.

The business activities of Enzo Biochem are performed by the company’s three wholly owned subsidiaries . . . Enzo Life Sciences, Enzo Therapeutics and Enzo Clinical Labs. Such activities include research and development, manufacturing and marketing of biomedical research products and tools through Enzo Life Sciences and research and development of therapeutic products through Enzo Therapeutics and the operation of a regional clinical reference laboratory through Enzo Clinical Labs.

Enzo Biochem, Inc. reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

The Company's financial condition remained strong, with working capital of $42.1 million. As of October 31, 2010, cash and cash equivalents, plus short term investments in US Treasury Bills, totaled $31.6 million. At November 30, 2010 Enzo’s cash, and cash equivalents and short-term investments were $33.9 million, which exceeded the July 31, 2010 balance by $0.3 million. Cash utilization in operations declined year over year by approximately $1 million to $1.8 million principally due to the reduced loss in the 2011 period. Management’s plan is to move towards being cash flow positive from operations in calendar 2011. There was no debt.

****************************************

Mosaic Co. (NYSE:MOS) will issue its second quarter fiscal 2011 earnings results and financial tables on Tuesday, January 4, 2011, after the close of trading on the New York Stock Exchange. Results will be available on Mosaic's website at mosaicco.com/investors. The Company will host a conference call with presentation slides on Wednesday, January 5, 2011, to discuss the results. The call will begin at 10:00 a.m. Eastern Standard Time (9:00 a.m. Central Standard Time) and will last no longer than 60 minutes.

The Mosaic Company engages in the production and marketing of concentrated phosphate and potash crop nutrients for the agriculture industry worldwide. The company produces phosphate crop nutrients for use in crop nutrients and feed phosphate for animal feed ingredients.

****************************************

Robbins & Myers Inc. (NYSE:RBN) announced that it will release results for first quarter fiscal 2011 ending November 30, 2010 before the market opens on Friday, January 7, 2011. A webcast has been scheduled for 2:00 p.m., ET on January 7, 2011. Peter C. Wallace, President and Chief Executive Officer, and Christopher M. Hix, Vice President and Chief Financial Officer, will discuss the Company's performance and respond to questions from the financial community.

Robbins & Myers, Inc., together with its subsidiaries, supplies engineered equipment and systems for various applications in energy, industrial, chemical, and pharmaceutical markets worldwide. The company operates in three segments: Fluid Management, Process Solutions, and Romaco.

****************************************

FMC Technologies, Inc. (NYSE:FTI) announced that it has signed an agreement with Statoil for the manufacture and supply of subsea production equipment to support the Vigdis North-East development. The award has a value of approximately $75 million in revenue to FMC Technologies. Vigdis North-East is a fast-track oil and gas field located in water depths of approximately 920 feet (280 meters) in the Norwegian sector of the North Sea. FMC's scope of supply includes the manufacture of four subsea trees, one manifold, subsea and topside control systems and an umbilical.

FMC Technologies, Inc. provides technology solutions for the energy industry and other industrial markets. It designs, manufactures, and services technologically sophisticated systems and products, such as subsea production and processing systems, surface wellhead systems, high pressure fluid control equipment, measurement solutions, and marine loading systems for the oil and gas industry.

**********************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

--- End ---

Click to Share

Contact Email:
***@drstockpick.com Email Verified
Source:Karl McMahon
Industry:Business, Finance, Stocks
Tags:biomedical, biotechnology, enz, enzo biochem, fmc, genetic process, life sciences, medicine, mosaic, nyse:enz, nyse:fti
Shortcut:prlog.org/11192253
Verified Account Email Address

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share